Psilocybin May Extend Lifespan, Study Reveals
New findings indicate that psilocybin, commonly known as magic mushrooms, might actually contribute to increased lifespan. Researchers at Emory University School of Medicine in Atlanta, Georgia, have discovered that this psychedelic compound extends cell lifespan and enhances survival rates in aging mice.
Psilocybin, defined in the study, is a naturally occurring psychedelic derived from certain mushrooms. The research highlights its potential, with considerable clinical evidence emerging regarding its ability to treat various psychiatric and neurodegenerative conditions.
Published in the journal Nature, this study provides the first experimental evidence that psilocin, which is the active metabolite of psilocybin, can actually increase the lifespan of older mice.
The researchers suggest that psilocybin could play a significant role in countering effects of aging. Louise Hecker, a co-author of the study, mentioned that the data indicates the compound influences multiple aspects of aging, including reducing oxidative stress and preventing DNA damage, which is associated with preserving telomere length—crucial structures at the ends of chromosomes that aid in cell protection.
Hecker stated, “Psilocybin appears to slow down the ‘wear’ associated with aging.” The treatment demonstrated substantial effects in extending cell life and enhancing survival even when given to mice in later stages of life, which is quite noteworthy.
Interestingly, the mice treated with psilocybin appeared healthier overall. They even grew darker fur after being previously white. Hecker pointed out that while previous knowledge of psilocybin largely focused on brain-related clinical outcomes, these studies reveal that it impacts the entire body.
Need for Further Research
Since these studies are pioneering in terms of examining psilocybin’s effects on aging, there are still many unanswered questions. Hecker posed inquiries regarding optimal administration protocols for humans and ideal ages for initiating treatment. There’s a sense that much is yet to be uncovered about psilocybin’s potential benefits and mechanisms.
Further research is essential to explore these points thoroughly and to determine whether treatment can effectively impact lifespan. Gabe Charambides, who founded the first legal psilocybin retreat in Oregon, described the findings as compelling. He noted that while many trials focus primarily on mental health issues, this study shines a light on physiological changes and markers of cellular aging.
While there are some anecdotal reports from retreat attendees experiencing relief from physical ailments, like chronic pain, the focus remains on adapting psilocybin treatments for humans differently than for mice, especially regarding screening and preparation.
Potential Risks Remain
Ryan Moss, chief science officer at Filament Health, emphasized safe administration of psychedelics. He warned about the possibility of negative experiences, including anxiety and hallucinations, during psychedelic sessions, which can pose health risks, particularly cardiovascular ones in some cases.
To address these concerns, he suggests that participants in clinical trials undergo comprehensive preparation and monitoring by qualified professionals during their sessions.
